<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Omega-3-acid ethyl esters (fish oil): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Omega-3-acid ethyl esters (fish oil): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Omega-3-acid ethyl esters (fish oil): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12275" href="/d/html/12275.html" rel="external">see "Omega-3-acid ethyl esters (fish oil): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F171381"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dialyvite Omega-3 Concentrate [OTC];</li>
<li>Fish Oil Concentrate [OTC];</li>
<li>Fish Oil High Potency [OTC];</li>
<li>Lovaza;</li>
<li>Maximum Red Krill [OTC];</li>
<li>Ocean Blue MiniCaps Omega-3 [OTC];</li>
<li>Odorless Coated Fish Oil [OTC];</li>
<li>Omega-3 Fish Oil Ex St [OTC];</li>
<li>Omega-3 Microgel [OTC];</li>
<li>Pro Nutrients Omega 3 [OTC];</li>
<li>Salmon Oil-1000 [OTC] [DSC];</li>
<li>Sam-E.P.A. [OTC];</li>
<li>Sea-Omega [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F171400"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, Omega-3 Fatty Acids</li></ul></div>
<div class="block doa drugH1Div" id="F171384"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81863c66-ac4f-45ff-b638-ded564c6efe2">Dietary supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement:</b> 1 to 2 capsules 3 times daily. <b>Note:</b> Composition of OTC products may vary significantly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5fe11c5-5429-4488-93aa-98e687a47477">Hypertriglyceridemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertriglyceridemia (adjunctive agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> All patients should receive general measures (ie, address modifiable causes, manage atherosclerotic cardiovascular disease [ASCVD] risk, implement lifestyle modification [eg, dietary changes, reduction in alcohol consumption]) and optimal low-density lipoprotein lowering therapy for 4 to 12 weeks before considering triglyceride lowering therapy. For patients whose triglycerides remain ≥500 mg/dL and who do not warrant icosapent ethyl for additional ASCVD risk reduction, any prescription strength omega-3 fatty acid (including icosapent ethyl) or a fibrate (fenofibrate preferred) is reasonable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34332805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34332805'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Lovaza: 4 g once daily <b>or</b> 2 g twice daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991608"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). EPA and DHA are not renally eliminated.</p></div>
<div class="block doha drugH1Div" id="F50988836"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F171385"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F171361"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (4%), dyspepsia (3%), eructation (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, atrial flutter</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased LDL cholesterol</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bleeding tendency disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F171373"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylactic reaction) to omega-3 fatty acids or any component of formulation.</p></div>
<div class="block war drugH1Div" id="F171359"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Bleeding, including serious events, has been reported; risk may be increased with concomitant anticoagulant/antiplatelet use. Prolongation of bleeding time not exceeding normal limits has also been observed; use with caution in patients with coagulopathy. Monitor for signs and symptoms of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fish allergy: Use with caution in patients with known allergy or sensitivity to fish and/or shellfish.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: ALT may increase without concurrent AST increase; periodically monitor hepatic transaminases in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: May increase LDL levels; periodically monitor LDL levels.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Atrial fibrillation: Atrial fibrillation (AF) or flutter may occur; risk increased in patients with a history of AF or flutter and within the first 2 to 3 months of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions associated with abnormal lipids: Manage concurrent conditions (eg, diabetes, hypothyroidism, excessive alcohol intake) that may contribute to lipid abnormalities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Should be used as an adjunct to diet therapy and exercise. Secondary causes of hyperlipidemia should be ruled out prior to therapy. The effect, if any, of omega-3 fatty acids on the risk of pancreatitis or cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia is not known. A number of OTC formulations containing omega-3 fatty acids are marketed as nutritional supplements; these do not have FDA-approved indications and may not contain the same amounts of the active ingredient.</p></div>
<div class="block dosfc drugH1Div" id="F25177479"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Lovaza: Each 1 g capsule contains the combination of EPA (~465 mg) and DHA (~375 mg) ethyl esters.</p></div>
<div class="block foc drugH1Div" id="F171368"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dialyvite Omega-3 Concentrate: 600 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lovaza: 1 g</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lovaza: 1 g [DSC] [contains soybean oil, tocopherol, dl-alpha (vit e)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ocean Blue MiniCaps Omega-3: 350 mg [gluten free, lactose free, sugar free; contains fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg, 500 mg, 1000 mg, 1 g</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fish Oil Concentrate: 1000 mg [gluten free, lactose free, milk free, no artificial color(s), no artificial flavor(s), no artificial sweetener, sodium free, starch free, sugar free, wheat free, yeast free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fish Oil High Potency: 1000 mg [dairy free, egg free, gluten free, no artificial color(s), no artificial flavor(s), starch free, sugar free, wheat free, yeast free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maximum Red Krill: 300 mg [gluten free; contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Omega-3 Fish Oil Ex St: 880 mg [gluten free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Omega-3 Microgel: 600 mg [gluten free, no artificial color(s), no artificial flavor(s)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salmon Oil-1000: 200 mg [DSC] [corn free, rye free, starch free, sugar free, wheat free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sam-E.P.A.: 200-300 MG [dye free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sea-Omega: 1000 mg [cholesterol free, corn free, gluten free, milk derivatives/products, no artificial color(s), no artificial flavor(s), sodium free, starch free, sugar free, yeast free; contains soybeans (glycine soja)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg [DSC], 1000 mg, 1200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Odorless Coated Fish Oil: 1000 mg [gluten free, lactose free, milk free, no artificial color(s), no artificial flavor(s), no artificial sweetener, starch free, sugar free, wheat free, yeast free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pro Nutrients Omega 3: 332.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F24526958"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422228"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Pro Nutrients Omega 3 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">332.5 mg (per each): $0.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Dialyvite Omega-3 Concentrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $0.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Lovaza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $9.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ocean Blue MiniCaps Omega-3 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">350 mg (per each): $0.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Omega-3-acid Ethyl Esters Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $0.22 - $4.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Sea-Omega Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $0.14</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F171371"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Lovaza: Administer with food. Administer whole; do not break, crush, dissolve, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release capsule should be administered whole. Do not break, crush, dissolve, or chew. If safety and efficacy of fish oil can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, re-evaluation of need for omega-3 therapy after bariatric surgery is advised due to known improvements in cholesterol profile.</p></div>
<div class="block use drugH1Div" id="F171370"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement:</b> As dietary supplements for patients at early risk of coronary artery disease.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommendations from the American Heart Association (AHA) state that patients without documented coronary heart disease (CHD) should eat a variety of fish, preferably oily fish (eg, salmon), at least twice a week, or daily in patients with documented CHD (AHA [Kris-Etherton 2002]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertriglyceridemia (Lovaza):</b> As an adjunct to diet to reduce triglyceride levels in adults with severe (≥500 mg/dL) hypertriglyceridemia.</p></div>
<div class="block mst drugH1Div" id="F1959598"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lovaza may be confused with LORazepam</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Omacor [multiple international markets] may be confused with Amicar brand name for aminocaproic acid [US]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) reported a case of a foam plastic cup dissolving after contact with the liquid contents from a Lovaza capsule. ISMP is requesting the manufacturer to add warnings to its labeling and that healthcare providers add Lovaza to their list of medications to not crush.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299789"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F171362"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Omega-3 Fatty Acids may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: Omega-3 Fatty Acids may enhance the antiplatelet effect of Ibrutinib. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F171375"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adequate intake of omega-3 fatty acids is recommended during pregnancy (IOM 2005; Nordgren 2017). Maternal use of supplements or dietary consumption of omega-3 fatty acids (containing eicosapentaenoic acid and docosahexaenoic acid) influences fetal concentrations (Büyükuslu 2017; Coletta 2010; Miles 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Triglyceride concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary interventions that include omega-3 fatty acids may be initiated. In women who develop very severe hypertriglyceridemia and are at risk for pancreatitis, use of prescription omega-3 fatty acid products may be considered (Avis 2009; Berglund 2012; Jacobson 2015; Wong 2015).</p></div>
<div class="block brc drugH1Div" id="F20548542"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 fatty acids are present in breast milk and dietary supplementation increases milk concentrations (IOM 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F171376"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Dietary modification is important in the control of severe hypertriglyceridemia. Maintain standard cholesterol-lowering diet during therapy.</p></div>
<div class="block mop drugH1Div" id="F171366"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Triglycerides and other lipids (LDL-C) should be monitored at baseline and periodically. In patients with hepatic impairment, monitor hepatic transaminase levels, particularly ALT, periodically. Signs/symptoms of bleeding.</p>
<p style="text-indent:0em;margin-top:2em;">
<i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (Stone 2013):</i> Consider evaluation for GI disturbances and skin changes during therapy.</p></div>
<div class="block pha drugH1Div" id="F171358"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reduction in the hepatic production of triglyceride-rich very low-density lipoproteins. Possible cellular mechanisms include inhibition of acyl CoA:1,2 diacylglycerol acyltransferase, increased hepatic mitochondrial and peroxisomal beta-oxidation, and a reduction in the hepatic synthesis of triglycerides. The mechanisms contributing to reduction of cardiovascular events are not completely understood but are likely multi-factorial (eg, increased eicosapentaenoic acid [EPA] composition from carotid plaques, increased circulating EPA/arachidonic acid ratio, inhibition of platelet aggregation).</p></div>
<div class="block phk drugH1Div" id="F25177458"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Directly absorbed in the small intestine. Administration with a high-fat meal results in an increased overall exposure of total and free baseline-adjusted EPA by ~140% and 80%, respectively, compared to fasting conditions; a 40% increase in AUC occurred for baseline-adjusted free DHA.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: EPA: ~88 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: EPA: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: EPA and DHA are mainly oxidized in the liver similar to fatty acids derived from dietary sources. EPA: minor via CYP-450.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: EPA: ~37 hours; DHA: ~46 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Following repeat dosing with low-fat meals for ~2 weeks (steady state): EPA: 5 to 8 hours; DHA: 5 to 9 hours.</p></div>
<div class="block phksp drugH1Div" id="F51154915"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Sex: Females tended to have more uptake of EPA into serum phospholipids than males. The clinical significance of this is unknown.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539860"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Julphar omegold | Lovaza | Megaza</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Omecap</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Megaza</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Omacor | Omega 3 biomo | Zodin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Degreasian | Omacor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Esters ethyliques d'acides omega 3 | Omacor</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nebbaro | Omacor | Prestylon</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Hemido | Lipemia | Sea oil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Corprotect | Dualtis | Omacor</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Corprotect</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cormega</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Megaza | Mytiomega</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Agemo | Blumeg | Omega 3 alfasigma | Omega 3 doc generici | Omega 3 mylan | Omega 3 sandoz | Trecor | Trioreg | Triscudil</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Megaza</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ajuco | Ausmega | Boryung omega 3 | Cicor | CKD Omega3 mini | Dongkoo omega 3 | Hanmi omega | Humega | Jeil omega3 | Mega m mini | Megatigy | Megatree | Miniflo | N maco | Newmacor | Newmetin | Newmetin mini | Omacan | Omacor | Omaron | Omasmini | Omatop | Omatree | Omecin | Omega one | Omega one pro | Ometer | Omethyl cutielet | Ometid cutielet | Ometin | Omg mini | Pharma omega | Prime omega | Sumega | Super mega | Tg well | Tgcor | Unimega | Unimega mini | Wellmacor mini</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Omega 3 acid ethyl esters | Triklo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Zidoril</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Omacor | Tevocor</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Omegana | Omipure</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lipomeg</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Omacor | Protector</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Omacor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19741526">
<a name="19741526"></a>Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? <i>Curr Opin Lipidol</i>. 2009;20(6):484-490. doi: 10.1097/MOL.0b013e3283319127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/19741526/pubmed" id="19741526" target="_blank">19741526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21683321">
<a name="21683321"></a>Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week study with an open-label Extension [Marine] trial. <i>Am J Cardiol</i>. 2011;108(5):682-690.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21683321/pubmed" id="21683321" target="_blank">21683321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22962670">
<a name="22962670"></a>Berglund L, Brunzell JD, Goldberg AC, et al, "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline," <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/22962670/pubmed" id="22962670" target="_blank">22962670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28987719">
<a name="28987719"></a>Büyükuslu N, Ovalı S, Altuntaş ŞL, Batırel S, Yiğit P, Garipağaoğlu M. Supplementation of docosahexaenoic acid (DHA) / Eicosapentaenoic acid (EPA) in a ratio of 1/1.3 during the last trimester of pregnancy results in EPA accumulation in cord blood. <i>Prostaglandins Leukot Essent Fatty Acids</i>. 2017;125:32-36. doi: 10.1016/j.plefa.2017.08.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/28987719/pubmed" id="28987719" target="_blank">28987719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21364848">
<a name="21364848"></a>Coletta JM, Bell SJ, Roman AS. Omega-3 Fatty acids and pregnancy. <i>Rev Obstet Gynecol</i>. 2010;3(4):163-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21364848/pubmed" id="21364848" target="_blank">21364848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11303007">
<a name="11303007"></a>Durrington PN, Bhatnagar D, Mackness MI, et al, “An Omega-3 Polyunsaturated Fatty Acid Concentrate Administered for One Year Decreased Triglycerides in Simvastatin Treated Patients With Coronary Heart Disease and Persisting Hypertriglyceridaemia,” <i>Heart</i>, 2001, 85(5):544-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/11303007/pubmed" id="11303007" target="_blank">11303007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22639290">
<a name="22639290"></a>Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. <i>J Clin Endocrinol Metab</i>. 2012;97(8):2589-2596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/22639290/pubmed" id="22639290" target="_blank">22639290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9865671">
<a name="9865671"></a>Harris WS, Ginsberg HN, Arunakul N, et al, “Safety and Efficacy of Omacor in Severe Hypertriglyceridemia,” <i>J Cardiovasc Risk</i>, 1997, 4(5-6):385-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/9865671/pubmed" id="9865671" target="_blank">9865671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine). <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids</i>. Washington, DC: The National Academies Press. 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26699442">
<a name="26699442"></a>Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2 [published correction appears in: J Clin Lipidol. 2016;10(1):211.]. <i>J Clin Lipidol</i>. 2015;9(6)(suppl):S1-S122.e1. doi: 10.1016/j.jacl.2015.09.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/26699442/pubmed" id="26699442" target="_blank">26699442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23110790">
<a name="23110790"></a>Kotwal S, Jun M, Sullivan D, et al, "Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis," <i>Circ Cardiovasc Qual Outcomes</i>, 2012, 5(6):808-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/23110790/pubmed" id="23110790" target="_blank">23110790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21078810">
<a name="21078810"></a>Kowey PR, Reiffel JA, Ellenbogen KA, et al, “Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation: A Randomized Controlled Trial,” <i>JAMA</i>, 2010, 304(21):2363-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21078810/pubmed" id="21078810" target="_blank">21078810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12438303">
<a name="12438303"></a>Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association (AHA). Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. <i>Circulation</i>. 2002;106(21):2747-2757. Erratum in <i>Circulation</i>. 2003;107(3):512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/12438303/pubmed" id="12438303" target="_blank">12438303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lovaza.2015.09">
<a name="Lovaza.2015.09"></a>Lovaza (omega-3-acid ethyl esters) [prescribing information]. Wixom, MI: Woodward Pharma Services LLC; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23265344">
<a name="23265344"></a>Macchia A, Grancelli H, Varini S, et al, “Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation,” <i>J Am Coll Cardiol</i>, 2013, 61(4):463–8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/23265344/pubmed" id="23265344" target="_blank">23265344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21849598">
<a name="21849598"></a>Miles EA, Noakes PS, Kremmyda LS, et al. The Salmon in Pregnancy Study: study design, subject characteristics, maternal fish and marine n-3 fatty acid intake, and marine n-3 fatty acid status in maternal and umbilical cord blood. <i>Am J Clin Nutr</i>. 2011;94(6 suppl):1986S-1992S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21849598/pubmed" id="21849598" target="_blank">21849598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502576">
<a name="21502576"></a>Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2011;123(20):2292-2333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21502576/pubmed" id="21502576" target="_blank">21502576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23128104">
<a name="23128104"></a>Mozaffarian D, Marchioli R, Macchia A, et al, "Fish Oil and Postoperative Atrial Fibrillation: The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) Randomized Trial," <i>JAMA</i>, 2012, 308(19):2001-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/23128104/pubmed" id="23128104" target="_blank">23128104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21844082">
<a name="21844082"></a>Nodari S, Triggiani M, Campia U, et al, “n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences after Electrical Cardioversion: A Prospective, Randomized Study,” <i>Circulation</i>, 2011, 124(10):1100-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21844082/pubmed" id="21844082" target="_blank">21844082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28245632">
<a name="28245632"></a>Nordgren TM, Lyden E, Anderson-Berry A, Hanson C. Omega-3 fatty acid intake of pregnant women and women of childbearing age in the United States: potential for deficiency? <i>Nutrients</i>. 2017;9(3).pii:E197. doi: 10.3390/nu9030197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/28245632/pubmed" id="28245632" target="_blank">28245632</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Omega-3 fatty acids [prescribing information]. Tempe, AZ: Century HealthCare Inc; received July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21840110">
<a name="21840110"></a>Papadakis EP, Sarigianni M, Mikhailidis DP, Mamopoulos A, Karagiannis V. Acute pancreatitis in pregnancy: an overview. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2011;159(2):261-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21840110/pubmed" id="21840110" target="_blank">21840110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22968891">
<a name="22968891"></a>Rizos EC, Ntzani EE, Bika E, et al, "Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Meta-analysis," <i>JAMA</i>, 2012, 308(10):1024-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/22968891/pubmed" id="22968891" target="_blank">22968891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28289069">
<a name="28289069"></a>Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. <i>Circulation</i>. 2017;135(15):e867-e884. doi: 10.1161/CIR.0000000000000482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/28289069/pubmed" id="28289069" target="_blank">28289069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11058707">
<a name="11058707"></a>Stalenhoef AF, de Graaf J, Wittekoek ME, et al, “The Effect of Concentrated n-3 Fatty Acids Versus Gemfibrozil on Plasma Lipoproteins, Low Density Lipoprotein Heterogeneity and Oxidizability in Patients With Hypertriglyceridemia,” <i>Atherosclerosis</i>, 2000, 153(1):129-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/11058707/pubmed" id="11058707" target="_blank">11058707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222016">
<a name="24222016"></a>Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013]. <i>Circulation</i>. 2013; doi: 10.1161/01.cir.0000437738.63853.7a.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/24222016/pubmed" id="24222016" target="_blank">24222016</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vascepa (omega-3-acid ethyl esters) [prescribing information]. Bridgewater, NJ: Amarin Pharma Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34332805">
<a name="34332805"></a>Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee.<i> J Am Coll Cardiol</i>. 2021;78(9):960-993. doi:10.1016/j.jacc.2021.06.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/34332805/pubmed" id="34332805" target="_blank">34332805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512474">
<a name="27512474"></a>Wong B, Ooi TC, Keely E. Severe gestational hypertriglyceridemia: A practical approach for clinicians. <i>Obstet Med</i>. 2015;8(4):158-167. doi: 10.1177/1753495X15594082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/27512474/pubmed" id="27512474" target="_blank">27512474</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10255 Version 428.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
